1104 / 1816
Molecular subtypes and residual disease
233 pts (from MSKCC) with stages 2-3 BC, NAC, mastectomy, PMRT 2000-2009
(50 Gy/25f, chest wall+supraclav, 40% axillary boost, 20% IMN boost, 14% scar
boost)
NAC: Anthracycline 10%, Taxane 6%, both 86%
99% had ALND, 36% had ypN2-3
HR+: 53%
HER2+: 23% (74% had trastuzumab)
TN:
24%
pCR: 14% (T and N site)